66results about How to "Meet clinical testing requirements" patented technology

The invention discloses an albumin detection reagent which comprises a diluent and a reaction reagent, wherein the diluent is composed of trihydroxymethyl amino buffer, surfactant, preservative, anti-bilirubin interference agent and vitamin C oxidase; and the reaction reagent is composed of buffer, surfactant, bromocresol green and freeze-drying protective agent. The detection reagent disclosed by the invention has favorable sensitivity, accuracy, precision and linearity, and can completely satisfy the clinical examination requirements.

The invention relates to a sample preparation kit for detecting neurofibromatosis 1 (NF1)-related gene mutation, and in particular relates to a product for detecting NF1-related gene by the massively parallel sequencing platform technology. The kit is that A, a capture probe is specially designed and prepared for all exon fragments of NF1 gene; B, an unique linker with a tag sequence is designed; C, RCP (Polymerase Chain Reaction) amplification is performed for the probe sequence through a primer; and D, the operation of capturing a targeted fragment after mixing is specially designed. A massively parallel sequencing platform prepared through the method and the kit is high in sample throughput, high in efficiency, and simple and convenient to operate, and the sequencing inspection cost is greatly decreased.

The invention relates to a primer group for rapid detection of 2019-nCoV based on a CRISPR technology and application thereof, and belongs to the technical field of gene detection of the CRISPR technology. The primer group comprises an Orf1ab gene amplification primer pair, an Orf1ab gene crRNA, an N gene amplification primer pair and an N gene crRNA. The primer group is adopted to detect 2019-nCoV by the CRISPR technology, the detection time of 2019-nCoV is shortened, and detection can be completed within 40-60min. A specific sequence combination is obtained through screening to serve as theprimer group for detection, the primer group has the advantages of being high in sensitivity and specificity, and the detection limit can reach 7.5copies. The primer group is adopted to conduct CRISPRdetection on 2019-nCoV, dependence on complex variable-temperature amplification instruments such as a qPCR instrument is eliminated, and the CRISPR-Cas technology has wide application prospects in the aspect of real-time diagnosis of 2019-nCoV.

The invention discloses a liquid reagent for determining N-acetyl-beta-D-glucosaminidase, which takes 5-(4-(3-methoxyl-phenylmethene-)-rhodanine-3-qmmonium acetate-N-acetylamino-beta-D-glucoside as substrate and is prepared by adding proper buffer solution, surfactant, preservative, stabilizer and the like. The liquid reagent has the advantages of large solubility of the substrate, strong stability, high detection sensitivity, convenient clinical detection, low detection cost and small outside interference for the detection result of N-acetyl-beta-D-glucosaminidase.

The invention discloses an anti-heparin interference leucine aminopeptidase measuring reagent, which consists of a reagent 1 and a reagent 2, wherein the reagent 1 and the reagent 2 comprises the following components in the concentration ranges: the reagent 1 comprises 50-500 mmol/L of buffer solution (pH (Potential of Hydrogen) of 3.0-6.0), 1-100 ml/L of anti-interference agent and 0.1-100 g/L of preservative; and the reagent 2 comprises 50-500 mmol/L of buffer solution (pH (Potential of Hydrogen) of 3.0-6.0), 1-100 ml/L of L-leucine-p-nitroxyl aniline, 1-100 g/L of stabilizer and 0.1-100 g/L of preservative. The anti-heparin interference leucine aminopeptidase measuring reagent has the advantages of good anti-heparin interference capacity, good stability and capability of completely meeting requirements of clinical inspection.

The invention belongs to the technical field of medical instruments, and relates to a disposable soft connecting band collection container and an anti-freezing vacuum blood taking needle of a bleeding opening. The disposable soft connecting band collection container is formed in the following mode that: a biological product anticoagulant coating layer is arranged on an inner cavity wall of a circular connector; one end of the connector is provided with a blood taking plastic duct; a vacuum valve is placed on the plastic duct; the other end of the plastic duct is provided with the circular connector; the inner cavity wall of the circular connector is provided with the biological product anticoagulant coating layer; one end of the connector is provided with a venous blood taking needle, while the other end is provided with a blood collection sample bottle needle; the blood collection sample bottle needle is connected with a blood collection sample bottle cap; the blood collection sample bottle cap is connected with a rubber plug; the rubber plug is connected with a blood collection sample bottle; and one side on the blood collection sample bottle close to the blood collection sample bottle cap is provided with a secondary bleeding opening. The disposable soft connecting band collection container and the anti-freezing vacuum blood taking needle of the bleeding opening can ensure that a blood sample generates no cruor and hemolysis so as to ensure the accuracy of the test result. The blood dosage during the test can be controlled flexibly so as to ensure repeated tests at any time or the addition of new testing items.

The invention relates to a determination reagent of a total bile acid. The reagent comprises two components, wherein the reagent 1 comprises a phosphate buffer, Thio-NAD (Nicotinamide Adenine Dinucleotide), Emulgen B-66 CTAB (Cetyltrimethyl Ammonium Bromide), NaCl, 2-hydroxypyridine-N-oxide; the reagent 2 comprises a glycinate buffer, dextran sulfate, EGTA (Ethylene Glycol Tetraacetic Acid), 3 alpha-HSD (Hydrogen Sterol Dehydrogenase), Emulgen B-66, NADH (Nicotinamide-adenine Dinucleotide Acid), and 2-hydroxypyridine-N-oxide. As the combination of the cation surfactant and the nonionic surfactant Emulgen B-66 is added, the interference of bilirubin can be effectively eliminated; the selected stabilizer is added in the product, so that the reagent can be stored for one year at 2-8 DEG C without influence on the properties; the substrate concentration and the ion strength can be adjusted to enable the recovery rate of the reagent to be more than 98%. The determination reagent disclosed by the invention has the advantages of high accuracy in determined results, strong anti-interference performance, good stability and the like.

The invention relates to a CRISPR (clustered regularly interspaced short palindromic repeat) detection primer group for mycoplasma pneumoniae and an application of the CRISPR detection primer group, and belongs to the technical field of gene detection of a CRISPR technology. The primer group comprises an amplification primer pair and crRNA (CRISPR-derived ribonucleic acid), wherein the amplification primer pair is used for amplifying a sequence shown as SEQ ID NO. (sequence identifier number) 1 of the mycoplasma pneumoniae; crRNA comprises an anchor sequence and a guide sequence; the anchor sequence specifically identifies a Cas protein; and the guide sequence is matched with a target sequence segment in the sequence of SEQ ID NO. 1. The primer group detects the mycoplasma pneumoniae through the CRISPR technology; the detection time of the mycoplasma pneumoniae is shortened; and the detection can be accomplished within 60min. A specific sequence combination obtained by screening acts as the primer group for detection, the primer group has the advantages of high sensitivity and strong specificity, and a limit of detection of the primer group can reach 30 copies. The primer group isused for the CRISPR detection of the mycoplasma pneumoniae, is independent of a complicated variable temperature amplification instrument such as a qPCR (quantitative polymerase chain reaction) instrument, and a CRISPR-Cas technology has wide application prospects in instant diagnosis of the mycoplasma pneumoniae.

The invention discloses a direct bilirubin detection reagent. The direct bilirubin detection reagent comprises diluents and reaction reagents. The diluents comprise a buffer 1, a surfactant, an antiseptic and ascorbate oxidase. The reaction reagents comprise a buffer 2, common salt, disodium ethylene diamine tetraacetate, hydroxylamine sulphate, etidronic acid, sodium persulfate, sulfuric acid, an antiseptic and a freeze-drying protective agent. The direct bilirubin detection reagent has good sensitivity, accuracy, precision and linearity and can satisfy clinical examination requirements.

The disclosed detection method for Abeta1-42 antibody comprises: covering solid holder by the Abeta1-42 protein fragment; adding the target sample into the holder to cultivate and clean the non-combined impurity; adding Abeta1-42 mono-clone antibody solution to cultivate and clean any the non-combined; detecting the content of combined component in the mixture. This invention has well accuracy and fit to quantitative detection in wide clinic application.

The invention discloses a primer for detecting alcohol metabolizing genes by the aid of pyrosequencing joint sequencing methods, and belongs to the technical field of biological detection. The primer comprises amplification primers shown as SEQ ID NO.1-4 and sequencing primers shown as SEQ ID NO.5-6. Biotin labeling is carried out by 5' ends of the primers shown as SEQ ID NO.1 and SEQ ID NO.3. The invention further discloses application of the primer to simultaneously detecting the polymorphism of SNP (single nucleotide polymorphism) loci rs671 of ALDH2 (acetaldehyde dehydrogenase 2) genes and SNP loci rs1229984 of ADH1B (alcohol dehydrogenase 1B) genes. The primer is high in detection throughput as compared with the traditional ordinary pyrosequencing with only single-SNP polymorphism detection capacity during sequencing reaction in each procedure, the detection time can be effectively shortened, and labor and the cost can be effectively reduced. Besides, the primer and the application have the advantages of accurate detection results, good specificity, high sensitivity, short detection cycle, simplicity in operation and capability of meeting clinical examination requirements.

The invention belongs to the technical field of medical instruments, and particularly relates to a disposable hard connecting band collection container and an anti-freezing vacuum blood taking needle of a bleeding opening. The disposable hard connecting band collection container is formed in the following mode that: an anticoagulant coating layer is arranged on an inner cavity wall of a circular connector; one end of the connector is provided with a venous blood taking needle; the rear part of the connector is provided with a vacuum valve; the other end of the connector is provided with the blood collection sample bottle needle; the blood collection sample bottle needle is connected with a blood collection sample bottle cap; the blood collection sample bottle cap is connected with a rubber plug; the rubber plug is connected with a blood collection sample bottle; and one side on the blood collection sample bottle close to the blood collection sample bottle cap is provided with one secondary bleeding opening. The disposable hard connecting band collection container and the anti-freezing vacuum blood taking needle of the bleeding opening have the advantages that: the anticoagulant coating layer is added on the basis of the conventional hard connection type blood taking needle so that blood flowing out of a body can contact an anticoagulant; a blood sample is ensured to generate no cruor and hemolysis so as to ensure the accuracy of the test result; and the secondary bleeding opening is added so that a clinical inspector can flexibly control the blood dosage during the test to ensure repeated tests at any time or add new testing items.

The invention discloses a leucine aminopeptidase detection reagent which is characterized by comprising a diluent and a reaction reagent, wherein the diluent is composed of a buffer solution, a surfactant, a preservative, a bilirubin interference remover and a vitamin C oxidase; and the reaction reagent is composed of a buffer solution, sodium chloride, L-leucine-4-nitroaniline, 0.1-1 g/L preservative and 10-30 g/L freeze-drying protective agent. The detection reagent disclosed by the invention has favorable sensitivity, accuracy, precision and linearity, and can completely satisfy the clinical examination requirements.

The invention discloses a familial deteriorating atrioventricular conduction block gene diagnosis kit, and is characterized in that the invention relates to the diagnosis kit for detecting familial deteriorating atrioventricular conduction block genes by a large-scale parallel sequencing platform NGS technique. The kit is mainly characterized in that: A, a capture probe is uniquely designed and prepared and aims at all exon fragments of genes SCN5A and TRPM4; B, a connector with a label sequence is uniquely designed; C, a probe sequence is subjected to PCR amplification by universal primers; and D, a uniquely designed target fragment after mixing is subjected to capture operation.

The invention discloses a primer and a method for detecting polymorphism of VKORC1 and CYP2C9 genes by adopting a pyrosequencing method, and belongs to the field of molecular biology examination. The primer comprises amplification upstream and downstream primers and sequencing primers of genes including VKORC1-1639G being more than A, CYP2C9430C being more than T, and CYP2C91075A being more than C. The method comprises specimen collection and DNA extraction, PCR (polymerase chain reaction) amplification reaction, gel electrophoresis on a PCR product and pyrosequencing, wherein a DNA extraction kit used in the specimen collection and DNA extraction step is prepared from lysis buffer liquid, adsorbent, rinsing buffer liquid and elution buffer liquid; the lysis buffer liquid is prepared from sodium chloride, sodium citrate, a denaturing agent, a reducing agent, ethylenediamine tetraacetic acid, ionic surfactant, absolute ethyl alcohol and ultra-pure water. In summary, the detection method provided by the invention has the advantages of an accurate detection result, high specificity, a short detection period, a simple operation, low cost and the like.

The invention discloses a sickbed control device. The sickbed control device is characterized by comprising a bedstead body, a first movable bed plate, a middle plate, a second movable bed plate, a first electric push rod, a second electric push rod, a first position sensor, a second position sensor and a controller, wherein the first position sensor and the second position sensor are used for detecting movement positions of the first movable bed plate and the second movable bed plate separately; when the first movable bed plate or the second movable bed plate moves to the preset position, transmission information is fed back to the controller. The invention further provides an automatic control method for a sickbed. According to the sickbed control device and the automatic control method for the sickbed, the state of the sickbed is quantified, uncertain factors in a test are reduced or even removed, and a passive leg raising test is automatically completed accurately step by step according to preset parameters of a user. According to the automatic control method for the sickbed, medical workers can be better assisted in safely and efficiently completing the passive leg raising test at high quality.

The invention discloses a differential diagnostic kit for myocardial hypertrophy genes. The differential diagnostic kit is characterized that the technology relates to the differential diagnostic kitfor detecting the myocardial hypertrophy genes by applying a large-scale parallel sequencing platform NGS (Next-Generation Sequencing) technique. The differential diagnostic kit is mainly characterized in that A, unique design and preparation of capture probes aiming at all exon fragments of genes such as ACTC1, ACTN2, ANKRD1, CALR3, CASQ2, CAV3, CSRP3, FHL1, JPH2, LDB3, MYBPC3, MYH6, MYH7, MYL2,MYL3, MYLK2, MYOZ2, MYPN, NEXN, PLN, PRKAG2, SLC25A4, TCAP, TNNC1, TNNI3, TNNT2, TPM1, TRIM63, TTN, VCL, GLA, TTR, LAMP2 and FLNC; B, unique design of a connector with a tag sequence; C, PCR (Polymerase Chain Reaction) amplification of the probe sequence by using a universal primer pair; D, capture operation of mixed target fragments with unique design.